P. Scott‐Stevens

发表

Optimization of a Series of RIPK2 PROTACs.

Aditya R. Thawani, I. E. Smith, R. Nagilla, 2021, Journal of medicinal chemistry.

Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs.

M. Bantscheff, N. Zinn, C. Chung, 2021, Angewandte Chemie.

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

Aditya R. Thawani, I. E. Smith, Carol A. Capriotti, 2020, Communications Biology.

Identification and Optimization of Novel Small c-Abl Kinase Activators Using Fragment and HTS Methodologies.

J. Cottom, N. Campobasso, P. Ward, 2019, Journal of medicinal chemistry.

First Administration of the Fc-Attenuated Anti-β Amyloid Antibody GSK933776 to Patients with Mild Alzheimer’s Disease: A Randomized, Placebo-Controlled Study

T. Fladby, H. Zetterberg, A. Wallin, 2015, PloS one.

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

Aditya R. Thawani, I. E. Smith, M. Bantscheff, 2020, Communications Biology.

Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans

J. Baron, T. Fryer, D. Wong, 2010, Journal of Pharmacology and Experimental Therapeutics.

GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice

J. Schofield, M. Convery, Xiping Zhang, 2021, The Journal of biological chemistry.

Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects.

J. Richardson, Z. Ali, S. McHugh, 2013, British journal of clinical pharmacology.

Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L‐838417

P. Worboys, J. Atack, P. Scott-Stevens, 2005, Biopharmaceutics & drug disposition.

Targeted protein degradation in vivo with Proteolysis Targeting Chimeras: Current status and future considerations.

L. Gaohua, G. Lu, G. Watt, 2019, Drug discovery today. Technologies.

Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders

Sara C. Humphreys, Donglu Zhang, C. Rynn, 2023, Drug Metabolism and Disposition.

Contribution of specific binding to the central benzodiazepine site to the brain concentrations of two novel benzodiazepine site ligands

R. Mckernan, A. Pike, J. Atack, 2007, Biopharmaceutics & drug disposition.

Aldehyde oxidase and its contribution to the metabolism of a structurally novel, functionally selective GABAA α5-subtype inverse agonist

D. O'connor, M. Braun, A. Macleod, 2006, Xenobiotica; the fate of foreign compounds in biological systems.

Comparison of Lorazepam [7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2H-1,4-benzodiazepin-2-one] Occupancy of Rat Brain γ-Aminobutyric AcidA Receptors Measured Using in Vivo [3H]Flumazenil (8-Fluoro 5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic Acid Ethyl Ester)

J. Baron, T. Fryer, J. Atack, 2007, Journal of Pharmacology and Experimental Therapeutics.

Comparison of Lorazepam [7-Chloro-5-(2-chlorophenyl)-1,3-dihydro-3-hydroxy-2 H -1,4-benzodiazepin-2-one] Occupancy of Rat Brain (cid:1) -Aminobutyric Acid A Receptors Measured Using in Vivo [ 3 H]Flumazenil (8-Fluoro 5,6-dihydro-5-methyl-6-oxo-4 H -imidazo[1,5- a ][1,4]benzodiazepine-3-carboxylic Ac

J. Baron, T. Fryer, J. Atack, 2007 .

An evaluation of a low-density DNA microarray using cytochrome P450 inducers.

F. de Longueville, V. Bertholet, G. Meneses‐Lorente, 2003, Chemical research in toxicology.